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Hypercholesterolemia aggravates radiocontrast nephrotoxicity: Protec-
tive role of L-arginine. It is well known that the radiocontrast-induced
ARF depends on risk factors often associated with compromised renal
circulation. Since studies have shown that endothelium-dependent vaso-
dilation is impaired in hypercholesterolemia (HC), we studied the effect of
radiocontrast (RC) administration (6 ml/kg body wt, via femoral artery) in
salt-depleted rats that were kept on a normal cholesterol (NC) or HC diet
(4% cholesterol and 1% cholic acid). Inulin clearance (CIn, ml/min/100 g
body wt), renal blood flow (RBF; electromagnetic flowmeter, ml/min/100
g body wt), and fractional excretions of sodium, potassium and water
(FENa, FEK and FEH2O, respectively), cholesterol (mg/dl), and albumin
(g/dl) were measured 24 hours after radiocontrast administration. The
administration of RC to HC rats (RCHC) resulted in lower values of CIn
compared with NC rats (RCNC) and control rats: 0.36 6 0.085 versus
0.76 6 0.13 (RCNC; P , 0.01), versus 0.84 6 0.03 (control HC; P , 0.01),
versus 0.87 6 0.06 (control NC; P , 0.01). Hypercholesterolemia per se
did not alter renal function, and control HC versus control NC was not
significant. Renal blood flow was significantly lower in the RCHC when
compared to RCNC (4.3 6 0.3 vs. 6.1 6 0.3; P , 0.001) and to control
animals (control HC 8.2 6 0.3; P , 0.001), and control NC 7.5 6 0.33 (P ,
0.001). To study the role of nitric oxide (NO), HC rats were treated with
an infusion of L-arginine or D-arginine (150 mg via femoral artery) in a 50
mg bolus before RC administration and the remaining dose continuously
for a period of one hour. The administration of L-arginine to RCHC rats
resulted in significantly higher CIn (0.86 6 0.1; P , 0.001) when compared
to the untreated rats (RCHC). D-arginine did not show a significant
difference in CIn (0.49 6 0.08). There was a considerable difference
between D-arginine RCHC and L-arginine RCHC (P , 0.05). The RBF
fall was prevented by L-arginine in RCHC (8.4 6 0.23 vs. 4.3 6 0.3; P ,
0.001), but it was not prevented by D-arginine (5.1 6 0.57; P , 0.001). Our
data suggest that hypercholesterolemia aggravates nephrotoxicity, which is
attenuated by L-arginine but not by D-arginine administration, suggesting
that nitric oxide plays a significant role in this model of acute renal failure.
Radiocontrast-induced acute renal failure (ARF) continues to
be a common cause of renal injury acquired in the hospital. The
incidence of ARF is highly dependent on the population exam-
ined and the criteria used to diagnose renal injury. Several studies
have demonstrated that diabetic nephropathy, volume depletion,
dehydration and pre-existing renal insufficiency are the most
important risk factors to the development of radiocontrast-in-
duced ARF [1–3]. Agmon et al have shown that nitric oxide (NO)
has an important protective role in the renal response to radio-
contrast material [4]. NO may participate in the balance of renal
medullary oxygenation and vasodilation, and thus may play an
important role in the prevention of medullary hypoxic injury [5, 6].
Reduced synthesis of these vasoactive substances in renal disease
may predispose patients to radiocontrast nephrotoxicity.
A substantial amount of experimental evidence exists indicating
that hypercholesterolemia impairs endothelium-dependent va-
sorelaxation, even before the development of atherosclerosis
[7–9].
Since many hypercholesterolemic patients are submitted to
imaging studies in clinical practice, we hypothesized that hyper-
cholesterolemia might be a risk factor for radiocontrast nephro-
toxicity. We studied the renal function 24 hours after radiocon-
trast administration in hypercholesterolemic salt-depleted rats. To
evaluate the possible role of NO in the pathogenesis of radiocon-
trast-induced acute renal failure (ARF) in this model, we admin-
istrated L-arginine, the endogenous substrate for NO synthesis, to
these hypercholesterolemic salt-depleted rats.
METHODS
The first part of this experiment was designed to evaluate the
potential role of hypercholesterolemia on radiocontrast-induced
ARF.
Male Wistar rats, weighing 150 to 250 g were used for all
experiments. Rats were maintained on a normal cholesterol (NC)
or hypercholesterol diet supplemented with 4% cholesterol and
1% cholic acid (HC) for two weeks. The NC and HC diets were
exactly the same composition with regard to proteins, carbohy-
drates, minerals and vitamins. Salt depletion was induced during
the second week by using a low-salt diet (0.06% salt) plus single
subcutaneous injection of furosemide, 2 mg/kg body wt, at the
beginning of the second week. We observed that rats assigned to
the NC or HC diets ingested equal amounts of food. Animals had
free access to water. To evaluate if there was any difference in the
volume status in hypercholesterolemic and normocholesterolemic
rats, we measured the plasma volume and the volume of distri-
bution of sodium.
To measure the Na space, 10 microcuries (mCi) of 22Na were
injected as a bolus in jugular vein, cannulated with PE50 in
anesthetized NC-rats and HC-rats. Blood samples were obtained
at four hours. The sodium space was determined from the
quotient of dose of 22Na injected in counts per minute divided by
the equilibrium counts per minute per milliliter of plasma.
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To determine the blood volume, six NC and seven HC anes-
thetized rats received 51Cr tagged human albumin, 25 mCi in bolus
intrajugular dissected vein that had been cannulated with PE60.
Blood samples were collected from the femoral dissected artery to
determine chromium activity at 10, 15, 20 and 25 minutes after
albumin injection. Plasma volume was determined from the
quotient of the dose of chromium injected in counts per minute
divided by the calculated counts per minute per milliliter of
plasma at time zero. The concentration of radioactive at time zero
was calculated by extrapolation of the minimum-square exponen-
tial regression line. Both 51Cr and 22Na were counted in a Cobra
5000 Packard counter model (Packard Instruments, Waltham,
MA, USA).
Radiocontrast (RC) ARF was induced in anesthetized rats
(pentobarbital, 50 mg/kg body wt, subcutaneously) by a bolus
injection of diatrizoate 6 ml/kg body wt intra-left femoral dis-
sected artery, cannulated with PE60. The control animals were
submitted to the same procedure except that they also received a
bolus of saline solution 6 ml/kg body wt. Rats were kept in
metabolic cages and 24 hours after RC injection, glomerular
filtration rate (GFR), renal blood flow (RBF), and fractional
excretion of sodium, potassium and water (FENa, FEK and
FEH2O, respectively) were measured. GFR was measured in
anesthetized rats (pentobarbital, 50 mg/kg body wt) by inulin
clearance (CIn). Inulin (100 mg/kg body wt) was injected as a
loading dose, followed by a continuous infusion of 0.27 mg/min.
Jugular veins were cannulated with PE60 for the administration of
inulin and fluids. A tracheotomy was performed and the rats were
maintained breathing spontaneously. The urinary bladder was
cannulated with PE240 through a small abdominal incision to
obtain urine sampling. Mean arterial blood pressure (MAP) was
recorded. After a 30-minute equilibration period, three urine
collections and blood samples (at the beginning and at the end)
were obtained. RBF was monitored at the end of the experiment,
by a perivascular transonic ultrasonic flow sensor (T-106; Tran-
sonic System Inc., Ithaca, NY, USA) with the probe mounted on
the left renal artery. Four groups were obtained from this first part
of the experiment: (1) N 5 8 control NC-rats; (2) N 5 10 control
HC-rats; (3) N 5 12 RCNC-rats; (4) N 5 11 RCHC-rats.
In the second part of the experiment, we treated the HC-rats
with L-arginine, the endogenous substrate for NO synthesis, to
investigate the potential role of NO in the RC-induced acute renal
failure in animals with hypercholesterolemia. Another HC-rat
group was treated with D-arginine, an inert isomer that is not a
substrate for NO synthesis.
Anesthetized HC animals were treated with an infusion of
L-arginine or D-arginine (150 mg intra-left femoral dissected
artery) in a 50 mg bolus before the RC administration, and then
the remaining dose was administered for a period of one hour.
MAP was recorded before and after the L-arginine or D-arginine
infusion. Rats were kept in metabolic cages, and 24 hours after
RC and L-arginine or D-arginine injection, GFR, RBF, FENa,
FEK and FEH2O were measured following the same procedures as
described in the first part of the experiment. Two groups were
obtained from this second part of the experiment: (1) N 5 9
LA-RCHC-rats, that is, those animals injected with L-arginine,
and (2) N 5 7 DA-RCHC-rats, those injected with D-arginine.
To evaluate the acute effect of radiocontrast administration,
the urinary excretion of nitrite (NO2) and nitrate (NO3), the
stable oxidation products of NO, was measured during the first
hour after radiocontrast administration. We studied six other
groups: control-NC (N 5 5); control-HC (N 5 5); RCNC (N 5 5);
RCHC (N 5 5); LA-RCHC (N 5 5); DA-RCHC (N 5 5). The
surgical preparation of these animals was the same as for the
other groups from the first and the second parts of the experi-
ment.
Inulin was determined by the anthrone method and the ions by
flame photometry in blood and urine. The volume of urine was
measured gravimetrically. The urinary NO2 1 NO3 concentration
was measured by reduction of NO3 to NO2 with the nitrate
reductase enzyme by the method of Bartholomew [10]. The NO2,
generated from NO3 by the nitrate reductase enzyme, and any
NO2 in the urine was detected and quantitated by the Griess
reaction [11, 12]. Urinary creatinine was measured by Jaffe´
method [13]. Plasma cholesterol was measured using enzymatic
colorimetric method (Ames SERA-PAK). Serum albumin was
measured by the colorimetric method (Proti 2; Wiener Lab.,
Argentina). The values obtained for the three clearance periods
were averaged for each rat.
Statistical analysis
All values are reported as means 6 standard error of the mean
(SEM). Data were analyzed by ANOVA test and the Student-
Newman-Keuls multiple comparison post-test.
RESULTS
Volume status
The results of measurements of plasma volume and sodium
space in rats after two weeks on a normocholesterol or hypercho-
lesterol diet are presented in Table 1. There is no difference in
volume status between the normocholesterolemic and hypercho-
lesterolemic rats.
Role of hypercholesterolemia in radiocontrast-induced acute
renal failure
The administration of RC to hypercholesterolemic rats
(RCHC) resulted in lower values of CIn (ml/min/100 g body wt)
compared with normocholesterolemic rats (RCNC) and control
rats (control HC and control NC): 0.36 6 0.085 versus 0.76 6 0.13
(RCNC; P , 0.01), versus 0.84 6 0.03 (control HC; P , 0.01),
versus 0.87 6 0.06 (control NC; P , 0.01). Hypercholesterolemia
Table 1. Volume of distribution of sodium and plasma volume were
measured after two weeks in rats underwent a normocholesterol or
hypercholesterol diet
Normocholesterolemic
rats
Hypercholesterolemic
rats P
Volume of
distribution
of 22Na,
ml/100 g body wt
27.9 6 1.7 (N 5 8) 30.2 6 0.9 (N 5 7) NS
Plasma volume,
ml/100 g body wt
4.8 6 0.2 (N 5 6) 4.6 6 0.2 (N 5 7) NS
Hematocrit % 43 6 1 44 6 1 NS
Blood volume,
ml/100 g body wt
8.2 6 0.1 8.3 6 0.1 NS
Salt depletion was induced during the second week by using a low-salt
diet plus a single dose of furosemide at the beginning of the second week.
Values are expressed as mean 6 standard error of mean. Data are
analyzed by Student’s unpaired test.
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per se did not alter renal function. The control HC versus control
NC value was not significant and CIn was normal in RCNC
(0.76 6 0.13) 24 hours after RC administration, despite salt
depletion (Fig. 1 and Table 2). RBF (ml/min/100 g body wt) was
significantly lower in the RCHC than in RCNC (4.3 6 0.3 vs.
6.1 6 0.3; P , 0.001) and than control animals (control HC 8.2 6
0.3, P , 0.001, and control NC 7.5 6 0.33, P , 0.001). Although
RC did not affect CIn in RCNC, it did decrease RBF compared
with control NC: 6.1 6 0.3 versus 7.5 6 0.33 (P , 0.01). There
were no significant differences in control HC versus control NC
rats (Fig. 1 and Table 2). These observations strongly imply that
hypercholesterolemia is a risk factor to the development of
RC-induced ARF in salt-depleted rats. Furthermore, RC mark-
edly altered the RBF in hypercholesterolemic rats and it caused a
slight decline in RBF in normocholesterolemic rats. There were
no significant differences in FENa, FEK, FEH2O among the four
groups. Urine volume was lower in RCHC and RCNC when
compared with control NC (Table 2).
Role of nitric oxide in radiocontrast-induced acute renal failure
The second series of experiments were performed in HC-rats.
In view of the above results, we decided to treat the animals with
L-arginine in order to study the role of NO. The administration of
L-arginine to RCHC-rats (group LA-RCHC) resulted in signifi-
cantly higher CIn (0.86 6 0.1; P , 0.001) compared with the
untreated rats (RCHC); there was no difference compared with
the control (control HC). Thus, L-arginine infusion resulted in a
complete reversal of the decrease of CIn seen in RCHC-rats. In
contrast, animals treated with D-arginine did not show a signifi-
cant difference in CIn (0.49 6 0.08) compared with the untreated
rats (RCHC). There was a considerable difference between
DA-RCHC and LA-RCHC (P , 0.05; Fig. 2 and Table 3). The
RBF fall was prevented by L-arginine in RCHC when compared
with untreated rats (8.4 6 0.23 vs. 4.3 6 0.3; P , 0.001).
Therefore, L-arginine was able to restore the RBF and there was
no difference when compared with the control group (control
HC). The RBF was significantly lower in rats treated with
D-arginine (0.49 6 0.08; P , 0.001) than in LA-RCHC, and there
was no difference with untreated rats (Fig. 2; Table 3). L-arginine
resulted in the prevention of the hemodynamic abnormalities seen
in RC-induced ARF in HC-rats. The RBF of the DA-RCHC rats
remained significantly decreased, showing that D-arginine could
not restore the hemodynamics, since D-arginine is not a substrate
for NO production. The group that received D-arginine (DA-
RCHC) unexpectedly produced a marked increase in FENa, FEK,
FEH2O and diuresis compared with the other groups. A diuretic
response was also seen with L-arginine (Table 3).
Measurements of total serum cholesterol in the six groups of
experiments are shown in Table 4. Rats fed a hypercholesterol
diet had serum cholesterol levels three to four times higher than
rats injesting the normocholesterol diet. As can be seen, although
there was no difference in body weights among the groups at the
start of the experiment, the HC-rats gained less weight during the
first two weeks. After two weeks there was no significant differ-
ence in serum albumin among the groups submitted to the
normocholesterol diet (2.9 6 0.1 g/dl) or hypercholesterol diet
(3.2 6 0.1 g/dl).
There was no difference in mean arterial pressures before and
after L-arginine or D-arginine infusion. When comparing blood
pressures measured during the clearance periods, there was no
significant difference among all of the groups (Table 4).
There was a slight tendency, though not statistically significant,
to increase the urinary NO2 1 NO3 excretion after radiocontrast
infusion in RCNC and RCHC, and this was similar in magnitude
to that of the LA-RCHC and DA-RCHC animals (Fig. 3).
DISCUSSION
In this study, we found that hypercholesterolemia can aggravate
radiocontrast nephrotoxicity in salt-depleted rats. This result is of
great importance considering that, despite the innovations in body
imaging techniques, the use of radiocontrast material is increasing
largely because of the need for angiography on dysfunctional
coronary arteries, heart and great vessels mainly among patients
with hypercholesterolemia. It is well known that the incidence of
radiocontrast nephropathy depends on a number of risk factors,
the best established of which are the chronic renal insufficiency
and diabetes mellitus [14–16]. Hypercholesterolemia has never
been described as a risk factor before. Many studies have showed
that multiple renal insults are necessary to produce radiocontrast
nephrotoxicity in both in vivo and in vitro experiments [1].
Although high doses of radiocontrast media administered to
normal animals may induce a transient reduction of glomerular
filtration rate, sustained renal failure is rarely produced. The
literature has described radiocontrast-induced nephrotoxicity in
animals preconditioned by salt-depletion and indomethacin [17,
Fig. 1. Inulin clearance (A) and renal blood flow (RBF; B) in normal
cholesterol (NC) and hypercholesterol (HC) salt-depleted rats before
(control groups) and after radiocontrast (RC) administration. Data are
SEM, and are analyzed by ANOVA. Descriptions of the groups are in the
text. cP , 0.01 vs. control NC, control HC and RCNC; 1P , 0.01 vs.
control NC and control HC; *P , 0.001 vs. control NC, control HC and
RCNC.
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18], in dogs with heart failure [19], in uninephrectomy [20], in
renal vasoconstriction induced by drugs like angiotensin II infu-
sion, and drugs that inhibited renal vasodilation [21–27]. With our
salt-depleted rats it was not necessary to give indomethacin to
induce acute renal failure after radiocontrast infusion. We dem-
onstrated that the GRF and renal blood flow were significantly
reduced 24 hours after radiocontrast administration in hypercho-
lesterolemic salt-depleted rats. This did not occur with normocho-
lesterolemic salt-depleted rats. In these animals, GRF was nor-
mal, although the renal blood flow was still slightly reduced, but
not as much as in the hypercholesterolemic rats. Schwartz et al
showed significant decrease in inulin clearance and paraamin-
ohippurate clearance 24 hours after radiocontrast administration
in salt-depleted rats [28]. These results are not in agreement with
our findings; however, their group induced a more severe form of
salt-depletion that began with furosemide administration four
days before the experiments. We administrated only a single dose
of furosemide one week before radiocontrast infusion and the
animals had free access to water. Despite these conditions, our
hypercholesterolemic rats developed a more serious and pro-
nounced decrease in RGF and RBF compared with normocho-
lesterolemic rats. Therefore, we concluded that hypercholesterol-
emia is a risk factor, since it was sufficient to aggravate the
radiocontrast nephrotoxicity. Thus, our study describes a new
model of acute renal failure induced by radiocontrast.
In hypercholesterolemic animals and humans, endothelium-
dependent relaxation is reduced and vasoconstriction is increased
[29–31]. Vessels isolated from normal animals exhibit an endo-
thelial dysfunction within minutes of exposure to cholesterol in
vitro [32–34]. The mechanism by which the hypercholesterolemia
can reduce the endothelium-dependent relaxation remains un-
clear, however, nitric oxide has been purported to play an
important role. Some studies show that administration of L-
arginine improves endothelium-dependent vasodilation in ani-
mals and humans [35, 36]. Oxidized low-density lipoprotein
(LDL) may chemically combine with and inactivate NO. Some
findings suggested that oxidized LDL can inhibit the activity of
nitric oxide synthase [37, 38]. In hypercholesterolemia, there may
be a reduction of NO synthesis or release, an increase of NO
degradation, and/or a competing vasoconstriction stimuli [39, 40].
Hypercholesterolemia may cause intracellular depletion of L-
arginine by reducing transmembrane transport [41, 42]. We did
not find a reduction in RBF in control hypercholesterolemic rats,
however, after radiocontrast administration they demonstrated a
high and prolonged vasoconstriction compared to the normocho-
lesterolemic rats. Most likely the kidney may be particularly
vulnerable to insults in this situation.
Brezis et al showed that radiocontrast injury occurs mainly in
the medullary thick ascending limbs of Henle’s loop [21]. Radio-
contrast given as a single insult produces little injury. Before its
administration, it is necessary to use a combination of insults that
can disturb the precise regulation of medullary blood flow. An
inhibition of nitric oxide synthesis can exacerbate renal failure,
Fig. 2. Inulin clearance (A) and renal blood flow (RBF; B) in hypercho-
lesterolemic salt-depleted rats before (control HC) and after 24 hours of
ratiocontrast (RCHC), radiocontrast plus L-arginine (LA-RCHC), and
radiocontrast plus D-arginine (DA-RCHC) administration. Data are SEM,
and are analyzed by ANOVA. Descriptions of the groups are in the text.
cP , 0.001 vs. control HC, and LA-RCNC; 1P , 0.05 vs. LA-RCHC; *P ,
0.01 vs. control HC.
Table 2. GFR, RBF, FENa, FEK, FEH2O and urine volume in control normocholesterolemic and hypercholesterolemic rats (control NC and control
HC), and after radiocontrast administration (RCNC and RCHC)
Groups
GFR RBF FENa FEK FEH2O Urine volume
ml/minml/min/100 g body wt %
Control NC 0.88 6 0.06 (8) 7.54 6 0.33 (8) 0.8 6 0.16 16.7 6 3.3 1.34 6 0.3 0.031 6 0.008de
Control HC 0.84 6 0.03 (10) 8.22 6 0.30 (8) 0.34 6 0.05 9.6 6 1.4 1.24 6 0.2 0.020 6 0.003
RCNC 0.76 6 0.13 (12) 6.15 6 0.31b (10) 0.81 6 0.22 21 6 5.2 1.16 6 0.3 0.014 6 0.002
RCHC 0.36 6 0.08a (11) 4.28 6 0.34c (7) 0.64 6 0.15 26.6 6 8.7 1.90 6 0.3 0.010 6 0.002
Data are means 6 standard error of mean. Numbers in parentheses are number of animals. Data are analyzed by one-way analysis of variance
(ANOVA). Abbreviations are: FEK, fractional excretion of potassium; FEH2O, fractional excretion of water; FENa, fractional excretion of sodium; GFR,
glomerular filtration rate; HC, hypercholesterol; NC, normal cholesterol; RBF, renal blood flow; RC, radiocontrast; RCNC, radiocontrast
normocholesterolemic group.
a P , 0.01 vs. control NC, control HC and RCNC
b P , 0.01 vs. control NC and control HC
c P , 0.001 vs. groups control NC, control HC, and RCNC
d P , 0.05 vs. RCNC
e P , 0.01 vs. RCHC
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inducing more extensive necrosis of medullar thick limbs. NO has
an important role in increasing medullary oxygenation and the
regulation of the blood flow in this area [5, 6]. Agmon et al
demonstrated that the combined administration of radiocontrast
and Nv-nitro-L-arginine methyl ester (L-NAME, to inhibit nitric
oxide synthesis) reduced medullary blood flow and creatinine
clearance [4]. In our experiment, intra-arterial infusion of L-
arginine, but not D-arginine, in hypercholesterolemic rats could
restore the RBF and renal function completely. The fact that
L-arginine had a significant effect on RBF and renal function in
hypercholesterolemic rats after radiocontrast administration al-
lows us to suppose that nitric oxide may play a role in this model
of acute renal failure.
Taken together, hypercholesterolemia is a risk factor because
Fig. 3. Urinary NO2 1 NO3 excretion (mM) in
normocholesterolemic (NC) and
hypercholesterolemic (HC) rats during the first
hour after radiocontrast (RC), radiocontrast
plus L-arginine (LA-RCHC), and radiocontrast
plus D-arginine (DA-RCHC). Data are analyzed
by ANOVA.
Table 3. Effects of L-arginine and D-arginine (150 mg/kg body wt i.v.) in hypercholesterolemic rats
Groups
GFR RBF FENa FEK FEH2O Urine volume
ml/minml/min/100 g body wt %
Control HC 0.83 6 0.03 (10) 8.2 6 0.30 (8) 0.34 6 0.05 9.6 6 1.4 1.24 6 0.2 0.020 6 0.003
RCHC 0.36 6 0.08 (11)a 4.3 6 0.34 (7)a 0.64 6 0.15 26.6 6 8.7 1.9 6 0.3 0.010 6 0.002
LA-RCHC 0.86 6 0.10 (9) 8.4 6 0.25 (8) 0.56 6 0.13 19.2 6 5.1 2.1 6 0.6 0.029 6 0.005g
DA-RCHC 0.49 6 0.08 (7)bc 5.1 6 0.57 (7)a 1.78 6 0.83d 69.4 6 15.8ef 6.2 6 1.8ef 0.049 6 0.010hi
Data are means 6 standard error of mean. Numbers in parentheses are number of animals. Data analyzed by one-way analysis of variance (ANOVA).
Abbreviations are: DA-RCHC, D-arginine administered to radiocontrast hypercholesterolemic group; FEK, fractional excretion of potassium; FEH2O,
fractional excretion of water; FENa, fractional excretion of sodium; GFR, glomerular filtration rate; HC, hypercholesterol; LA-RCHC, L-arginine
administered to radiocontrast hypercholesterolemic group; RBF, renal blood flow; RC, radiocontrast; RCNC, radiocontrast normocholesterolemic
group.
a P , 0.001 vs. control HC and LA-RCNC
b P , 0.01 vs. control HC
c P , 0.05 vs. LA-RCHC
d P , 0.05 vs. control HC and RCHC
e P , 0.001 vs. control HC
f P , 0.01 vs. RCHC and LA-RCHC
g P , 0.05 vs. RCHC
h P , 0.001 vs. control HC and RCHC
i P , 0.05 vs. LA-RCHC
Table 4. MAP before and 60 minutes after D- or L-arginine infusion, and during clearance (CI) periods
Groups
MAP mm Hg
Body weight, g CH mg dl
Baseline
After LA or
DA infusion
During CI
periods Initial Final Final
Control NC 122 6 3.8 174 6 5 262 6 17 54 6 5.0c
Control HC 120 6 2.8 165 6 6 205 6 9.0ab 194 6 11
RCNC 126 6 1.6 158 6 4 241 6 6.0 50 6 2.5c
RCHC 126 6 5.4 157 6 5 205 6 10ab 186 6 6.0
LA-RCHC 124 6 3.3 125 6 4.1 118 6 2.2 174 6 8 199 6 8.0ab 187 6 4.4
DA-RCHC 121 6 3.2 128 6 3.5 117 6 4.3 168 6 8 227 6 13 194 6 14
Table shows the initial body weight and two weeks later on normal or hypercholesterol diet, also final plasma total cholesterol (CH). Values are
expressed as mean 6 standard error of mean. Data analyzed by one-way analysis of variance (ANOVA). Comparisons between MAP before and after
D- or L-arginine infusion were calculated by Student’s paired test. Abbreviations are in Tables 2 and 3.
a P , 0.01 vs. Control NC
b P , 0.05 vs. RCNC
c P , 0.001 vs. Control HC, RCHC, LA-RCHC and DA-RCHC
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radiocontrast administration causes a profound decrease in RBF
and GFR in this pre-existing condition. The administration of
L-arginine allows us to conclude that NO can prevent the
vasoconstriction and decrease in GFR that is induced by the
administration of radiocontrast to HC-rats.
Rats receiving D-arginine had a significant increase in FENa,
FEK, FEH2O and diuresis compared with the other groups. Zager
and Vekatachalam have demonstrated that an infusion of amino
acids can exacerbate the ischemia-induced decline in GFR [43]. In
our study D-arginine infusion resulted in marked natriuretic,
kaliuretic and diuretic responses, which suggest an aggravation of
tubular injury or a diuretic effect on the proximal tubule [44]. This
was not observed with L-arginine since it was metabolized into
nitric oxide.
There is a slight tendency, though not statistically significant,
for an increased urinary NO2 1 NO3 excretion after radiocontrast
infusion, probably because radiocontrast imposes a large osmotic
load on tubules. Baylis et al have shown that NO2 1 NO3 is
normally extensively reabsorbed in the proximal tubule, and that
inhibition of proximal reabsorption therefore leads to a large
increase in NO2 1 NO3 excretion, as observed with acetazolamide
[44]. This could also explain why D-arginine infusion had a
tendency to increase the NO2 1 NO3 excretion.
Taken collectively, our results indicate that: (a) hypercholester-
olemia predisposes to radiocontrast induced nephropathy in
salt-depleted rats; (b) this may be an important new model for
radiocontrast-induced acute renal failure; (c) administration of
L-arginine prevents the decrease in GFR and RBF in radiocon-
trast induced nephropathy.
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APPENDIX
Abbreviations used in this article are: ARF, acute renal failure; CIn,
inulin clearance; DA-RCHC, D-arginine administered to radiocontrast 1
hypercholesterolemic group; FEK, fractional excretion of potassium;
FEH2O, fractional excretion of water; FENa, fractional excretion of so-
dium; GFR, glomerular filtration rate; HC, hypercholesterol; LA-RCHC,
L-arginine administered to radiocontrast 1 hypercholesterolemic group;
MAP, mean arterial pressure; NC, normal cholesterol; NO, nitric oxide;
NO2, nitrite; NO3, nitrate; RBF, renal blood flow; RC, radiocontrast;
RCHC, radiocontrast 1 hypercholesterolemic group; RCNC, radiocon-
trast 1 normocholesterolemic group.
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